Olopatadine PCD Pharma Franchise Company
Cafoli Lifecare is a dependable Olopatadine PCD pharma franchise company in India, offering 6 Olopatadine formulations across eye drops and eye/ear drops within its ophthalmology portfolio. All products are manufactured at WHO-GMP certified, DCGI-approved facilities and offered to franchise partners with exclusive district-wise monopoly rights.
What is Olopatadine?
Olopatadine is a dual-acting anti-allergic agent. It is a selective histamine H1 receptor antagonist and also a mast cell stabiliser, preventing the degranulation of mast cells and the release of histamine and other inflammatory mediators. This dual mechanism gives it both rapid symptomatic relief of itching and redness and a preventive effect on subsequent allergic responses, which is why it is a mainstay of treatment for allergic conjunctivitis. Compound data is available on PubChem.
Available Olopatadine Formulations
The Cafoli Lifecare Olopatadine range comprises 6 formulations in the following dosage forms:
Brand names, compositions, pack sizes and net rates are shared with registered franchise enquiries. Contact our team for the current Olopatadine price list.
Therapeutic Applications of Olopatadine
Prescribed under medical supervision for:
- Seasonal allergic conjunctivitis
- Perennial allergic conjunctivitis
- Vernal keratoconjunctivitis, as part of a specialist regimen
- Ocular itching, redness and watering associated with allergy
Prescriber specialties: ophthalmologists primarily, with additional prescribing by consulting physicians, paediatricians and ENT specialists. Olopatadine is a prescription-only medicine.
Why Olopatadine is a High-Potential Molecule for Distributors
Ophthalmic products are one of the most protected niches in Indian PCD pharma. Pack values are modest, but the segment sees far less price erosion than oral generics, because chemists rarely substitute an eye drop and the prescription tends to follow the ophthalmologist's brand. Allergic conjunctivitis is also extremely common in India — driven by dust, pollution and sharply seasonal pollen and post-monsoon peaks — so demand is high-volume and predictably cyclical, and a distributor who stocks ahead of allergy season captures the surge. Olopatadine specifically benefits from being the ophthalmologist's preferred dual-action agent rather than a commodity antihistamine drop, which supports brand loyalty. And because allergic eye disease recurs every year in the same patients, repeat purchase is built into the indication itself.
Why Choose Cafoli Lifecare
- Monopoly rights — exclusive district-wise marketing rights for the Olopatadine range
- WHO-GMP certified manufacturing and DCGI-approved products
- Promotional inputs — visual aids, MR bags, prescription pads, samples and reminder cards
- 1000+ franchise partners across India with an on-time dispatch record
- Transparent net rates and dedicated franchise support
References
- PubChem — Olopatadine compound record
- PubMed — Olopatadine in allergic conjunctivitis
- MedlinePlus — Drugs, Herbs and Supplements
Our formulations of Olopatadine find application in many critical therapeutic areas. Its therapeutic spectrum includes, but is not limited to: